A Phase 2 interventional study of Oral Lenacapavir and F/TAF in HIV-1-infection, sponsored by Gilead Sciences. Completed at 53 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-02.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the efficacy of lenacapavir (formerly GS-6207) containing regimens in people living with human immunodeficiency virus (HIV) (PLWH).
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Induction phase: Participants will receive lenacapavir (LEN) 600 mg (2 X 300 mg, tablet) orally on Days 1 and 2, followed by LEN 300 mg tablet orally on Day 8 plus emtricitabine/ tenofovir alafenamide (F/TAF) (200/25 mg) fixed-dose combination (FDC) tablets once daily orally from Day 1 to Week 28 plus LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via subcutaneous (SC) injection on Day 15. Maintenance phase: Participants will receive LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Week 28 and every 6 months (26 weeks) thereafter plus TAF 25 mg tablets once daily orally at Week 28 and will continue up to Week 80. Participants willing to continue the study beyond Week 80 will continue to receive SC LEN 927 mg injection every 6 months (26 weeks) and oral daily TAF 25 mg tablets from Week 80 onwards.
Drug: Oral Lenacapavir · Drug: F/TAF · Drug: Subcutaneous Lenacapavir · Drug: TAF
Induction phase: Participants will receive LEN 600 mg (2 X 300 mg, tablet) orally on Days 1 and 2, followed by LEN 300 mg tablet orally on Day 8 plus F/TAF (200/25 mg) FDC tablets once daily orally from Day 1 to Week 28 plus LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Day 15. Maintenance phase: Participants will receive LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Week 28 and every 6 months (26 weeks) thereafter plus bictegravir (BIC) 75 mg tablets once daily orally at Week 28 and will continue up to Week 80. Participants willing to continue the study beyond Week 80 will continue to receive SC LEN 927 mg injection every 6 months (26 weeks) and oral daily BIC 75 mg tablets from Week 80 onwards.
Drug: Oral Lenacapavir · Drug: F/TAF · Drug: Subcutaneous Lenacapavir · Drug: BIC
Induction phase: Participants will receive LEN 600 mg (2 X 300 mg, tablet) orally on Days 1 and 2, followed by LEN 300 mg tablet orally on Day 8 plus F/TAF (200/25 mg) FDC tablets once daily orally from Day 1 to Week 28 plus LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Day 15. Maintenance phase: Participants will receive LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Week 28 and every 6 months (26 weeks) thereafter plus bictegravir (BIC) 75 mg tablets once daily orally at Week 28 and will continue up to Week 80. Participants willing to continue the study beyond Week 80 will continue to receive SC LEN 927 mg injection every 6 months (26 weeks) and oral daily BIC 75 mg tablets from Week 80 onwards.
Drug: Oral Lenacapavir · Drug: F/TAF
Participants will receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) (50/200/25 mg) FDC tablets once daily orally from Day 1 and throughout their participation in the study up to Week 80
Drug: B/F/TAF
Tablets administered without regard to food
Also known as: GS-6207
Drug pages: Emtricitabine · Tenofovir alafenamide
Tablets administered without regard to food
Also known as: Descovy®
Administered in the abdomen via subcutaneous injections
Also known as: GS-6207
Tablets administered without regard to food
Tablets administered without regard to food
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
Tablets administered without regard to food
Also known as: Biktarvy®
Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 54 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 54 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 54 window was between Day 323 and 413 (inclusive). Percentages were rounded off.
Time frame: Week 54
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 28 as Determined by the US FDA-defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 28 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 28 window was between Days 176 and 231 (inclusive). Percentages were rounded off.
Time frame: Week 28
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 38 as Determined by the US FDA-defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 38 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 38 window was between Days 232 and 322 (inclusive). Percentages were rounded off.
Time frame: Week 38
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 80 as Determined by the US FDA-defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 80 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The Week 80 window was between Days 505 and 595 (inclusive). Percentages were rounded off.
Time frame: Week 80
Change From Baseline in Log10 HIV-1 RNA at Week 28
Time frame: Baseline, Week 28
Change From Baseline in Log10 HIV-1 RNA at Week 38
Time frame: Baseline, Week 38
Change From Baseline in Log10 HIV-1 RNA at Week 54
Time frame: Baseline, Week 54
Change From Baseline in Log10 HIV-1 RNA at Week 80
Time frame: Baseline, Week 80
Change From Baseline in Clusters of Differentiation 4+ (CD4+) Cell Count at Week 28
Time frame: Baseline, Week 28
Change From Baseline in CD4+ Cell Count at Week 38
Time frame: Baseline, Week 38
Change From Baseline in CD4+ Cell Count at Week 54
Time frame: Baseline, Week 54
Change From Baseline in CD4+ Cell Count at Week 80
Time frame: Baseline, Week 80
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
TEAEs were defined as 1 or both of any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off.
Time frame: Up to 174.9 weeks
Percentage of Participants Who Experienced Maximum Postbaseline Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline visit, up to last exposure date for participants who permanently discontinued study drug. Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening. Percentages were rounded off.
Time frame: Up to 174.9 weeks
Pharmacokinetics (PK) of LEN: Plasma LEN Pre-dose Concentrations for SC LEN
Time frame: Day 2, 8, Day 1 SC (Day 15), Week 28 and Week 54
PK of LEN : Plasma LEN Single Anytime Concentrations for the Oral LEN + DVY
Time frame: Day 2, 8, 15 , Week 28 and Week 54
PK of TAF (Tenofovir Alafenamide) and TFV (Tenofovir): Area Under the Concentration Versus Time Curve (AUClast) on Day 1
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2) and at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 and 2 on Day 1.
Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose on Day 1
PK of TAF and TFV (Tenofovir): Maximum Observed Concentration of Drug (Cmax) on Day 1
Cmax is defined as the maximum observed concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 and 2 on Day 1.
Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose on Day 1
PK of TAF and TFV: Time (Observed Time Point) of Cmax (Tmax) on Day 1
Tmax is defined as the time (observed time point) of Cmax. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 and 2 on Day 1.
Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose on Day 1
PK of TFV: Last Observed Quantifiable Concentration of the Drug (Clast) on Day 1
Clast is defined as the last observable concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK sub study analysis was conducted for Group 1 and 2 on Day 1.
Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose on Day 1
PK of TAF and TFV: AUClast at Weeks 16, 22, or 28
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A PK substudy was conducted in at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. For each participant, PK samples were taken at only one of the three possible visits: Weeks 16, 22, or 28. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
PK of TAF and TFV: Cmax at Weeks 16, 22, or 28
Cmax is defined as the maximum observed concentration of drug. A PK substudy was conducted in at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. For each participant, PK samples were taken at only one of the three possible visits: Weeks 16, 22, or 28. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
PK of TAF and TFV: Tmax at Weeks 16, 22, or 28
Tmax is defined as the time (observed time point) of Cmax. A PK substudy was conducted in at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. For each participant, PK samples were taken at only one of the three possible visits: Weeks 16, 22, or 28. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
PK of TFV: Clast at Weeks 16, 22, or 28
Clast is defined as the last observable concentration of drug. A PK substudy was conducted in at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TFV was summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. For each participant, PK samples were taken at only one of the three possible visits: Weeks 16, 22, or 28. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
PK of TAF: AUClast at Week 38
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF was summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 at Week 38.
Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
PK of TAF: Cmax at Week 38
Cmax is defined as the maximum observed concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF was summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 at Week 38.
Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
PK of TAF: Tmax at Week 38
Tmax is defined as the time (observed time point) of Cmax. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF was summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 at Week 38.
Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
PK of Tenofovir Diphosphate (TFV-DP): AUClast at Weeks 4, 10, 16, or 22
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A peripheral blood mononuclear cell (PBMC) substudy was conducted in a total of approximately 15 participants in Treatment Groups 1 and 2. For each participant, PK samples were taken at only one of the four possible visits: Weeks 4, 10, 16, or 22. A 12-hour postdose sample was collected, if possible. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
Time frame: 0 hours (Predose) and at 1, 2, and 6 hours postdose
PK of TFV-DP: Cmax at Weeks 4, 10, 16, or 22
Cmax is defined as the maximum observed concentration of drug. A PBMC substudy was conducted in a total of approximately 15 participants in Treatment Groups 1 and 2. For each participant, PK samples were taken at only one of the four possible visits: Weeks 4, 10, 16, or 22. A 12-hour postdose sample was collected, if possible. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
Time frame: 0 hours (Predose) and at 1, 2, and 6 hours postdose
PK of TFV-DP: Tmax at Weeks 4, 10, 16, or 22
Tmax is defined as the time (observed time point) of Cmax. A PBMC substudy was conducted in a total of approximately 15 participants in Treatment Groups 1 and 2. For each participant, PK samples were taken at only one of the four possible visits: Weeks 4, 10, 16, or 22. A 12-hour postdose sample was collected, if possible. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
Time frame: 0 hours (Predose) and at 1, 2, and 6 hours postdose
PK of Bictegravir (BIC): AUClast at Week 38
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). At Week 38, samples were analyzed for BIC only in Treatment Group 2.
Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
PK of BIC: Cmax at Week 38
Cmax is defined as the maximum observed concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). At Week 38, samples were analyzed for BIC only in Treatment Group 2.
Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
PK of BIC: Tmax at Week 38
Tmax is defined as the time (observed time point) of Cmax. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). At Week 38, samples were analyzed for BIC only in Treatment Group 2.
Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
PK of BIC: Clast at Week 38
Clast is defined as the last observable concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). At Week 38, samples were analyzed for BIC only in Treatment Group 2.
Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
Participants were enrolled at study sites in Dominican Republic, Puerto Rico, and the United States.
| Milestone | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF |
|---|---|---|---|---|
| Started | 52 | 53 | 52 | 26 |
| Completed | 41 | 35 | 36 | 24 |
| Not completed | 11 | 18 | 16 | 2 |
| Withdrew: Withdrew consent | 3 | 10 | 3 | 1 |
| Withdrew: Lost to follow-up | 3 | 5 | 11 | 0 |
| Withdrew: Investigator's discretion | 2 | 2 | 0 | 0 |
| Withdrew: Randomized but never treated | 0 | 0 | 0 | 1 |
| Withdrew: Death | 1 | 0 | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 0 | 0 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 54 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 54 window was between Day 323 and 413 (inclusive). Percentages were rounded off.
| percentage of participants | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF |
|---|---|---|---|---|
| Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 54 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm | 90.4 | 84.9 | 84.6 | 92.0 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 28 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 28 window was between Days 176 and 231 (inclusive). Percentages were rounded off.
| percentage of participants | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF |
|---|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 28 as Determined by the US FDA-defined Snapshot Algorithm | 94.2 | 92.5 | 94.2 | 100.0 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 38 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 38 window was between Days 232 and 322 (inclusive). Percentages were rounded off.
| percentage of participants | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF |
|---|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 38 as Determined by the US FDA-defined Snapshot Algorithm | 90.4 | 88.7 | 88.5 | 96.0 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 80 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The Week 80 window was between Days 505 and 595 (inclusive). Percentages were rounded off.
| percentage of participants | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF |
|---|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 80 as Determined by the US FDA-defined Snapshot Algorithm | 86.5 | 75.5 | 86.5 | 92 |
| log10 copies/mL | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF |
|---|---|---|---|---|
| Change From Baseline in Log10 HIV-1 RNA at Week 28 | -2.92 ± 0.649 | -3.04 ± 0.638 | -3.01 ± 0.716 | -3.07 ± 0.774 |
| log10 copies/mL | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF |
|---|---|---|---|---|
| Change From Baseline in Log10 HIV-1 RNA at Week 38 | -2.96 ± 0.639 | -3.06 ± 0.641 | -3.02 ± 0.771 | -3.04 ± 0.760 |
| log10 copies/mL | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF |
|---|---|---|---|---|
| Change From Baseline in Log10 HIV-1 RNA at Week 54 | -2.95 ± 0.636 | -3.12 ± 0.589 | -2.85 ± 0.840 | -3.08 ± 0.787 |
| log10 Copies/mL | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF |
|---|---|---|---|---|
| Change From Baseline in Log10 HIV-1 RNA at Week 80 | -2.96 ± 0.539 | -3.08 ± 0.592 | -2.96 ± 0.747 | -3.09 ± 0.755 |
| cells/µL | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF |
|---|---|---|---|---|
| Change From Baseline in Clusters of Differentiation 4+ (CD4+) Cell Count at Week 28 | 172 ± 178.2 | 158 ± 164.1 | 206 ± 154.6 | 163 ± 157.7 |
| cells/µL | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF |
|---|---|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 38 | 195 ± 164.6 | 220 ± 187.5 | 211 ± 166.2 | 232 ± 209.3 |
| cells/µL | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF |
|---|---|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 54 | 204 ± 189.1 | 213 ± 187.2 | 220 ± 175.5 | 193 ± 191.1 |
| cells/μL | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF |
|---|---|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 80 | 275 ± 211.8 | 262 ± 184.4 | 245 ± 237.4 | 248 ± 218.7 |
TEAEs were defined as 1 or both of any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off.
| percentage of participants | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF |
|---|---|---|---|---|
| Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) | 98.1 | 88.7 | 90.4 | 84.0 |
Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline visit, up to last exposure date for participants who permanently discontinued study drug. Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening. Percentages were rounded off.
| percentage of participants | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF |
|---|---|---|---|---|
| Grade 1 | 9.6 | 3.8 | 9.6 | 0 |
| Grade 2 | 55.8 | 56.6 | 42.3 | 76.0 |
| Grade 3 | 17.3 | 28.3 | 30.8 | 24.0 |
| Grade 4 | 13.5 | 9.4 | 13.5 | 0 |
| ng/mL | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) |
|---|---|---|
| Day 2 | 28.3 ± 27.15 | 26.1 ± 20.46 |
| Day 8 | 34.5 ± 20.96 | 32.1 ± 14.71 |
| Day 1 SC (Day 15) | 30.9 ± 16.76 | 31.2 ± 14.66 |
| Week 28 | 22.0 ± 11.70 | 23.0 ± 14.81 |
| Week 54 | 26.9 ± 14.19 | 26.4 ± 12.10 |
| ng/mL | Group 3: Oral LEN + F/TAF |
|---|---|
| Day 2 | 29.8 ± 42.70 |
| Day 8 | 78.7 ± 55.90 |
| Day 15 | 97.2 ± 67.25 |
| Week 28 | 96.6 ± 76.40 |
| Week 54 | 98.4 ± 85.25 |
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2) and at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 and 2 on Day 1.
| hours*nanogram/mL (h*ng/mL) | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) |
|---|---|---|
| TAF | 298.0 ± 88.0 | 260.0 ± 63.5 |
| TFV | 27.1 ± 27.9 | 40.5 ± 59.7 |
Cmax is defined as the maximum observed concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 and 2 on Day 1.
| ng/mL | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) |
|---|---|---|
| TAF | 278.8 ± 87.7 | 318.4 ± 57.7 |
| TFV | 5.4 ± 26.5 | 13.8 ± 160.2 |
Tmax is defined as the time (observed time point) of Cmax. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 and 2 on Day 1.
| hours | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) |
|---|---|---|
| TAF | 0.50 (0.50 to 1.00) | 0.50 (0.50 to 0.50) |
| TFV | 1.50 (1.00 to 2.02) | 1.00 (0.50 to 1.17) |
Clast is defined as the last observable concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK sub study analysis was conducted for Group 1 and 2 on Day 1.
| ng/mL | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) |
|---|---|---|
| PK of TFV: Last Observed Quantifiable Concentration of the Drug (Clast) on Day 1 | 2.7 ± 23.1 | 3.9 ± 38.0 |
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A PK substudy was conducted in at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. For each participant, PK samples were taken at only one of the three possible visits: Weeks 16, 22, or 28. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
| h*ng/mL | Group 3: Oral LEN + F/TAF |
|---|---|
| TAF | 231.2 ± 60.0 |
| TFV | 173.1 ± 52.5 |
Cmax is defined as the maximum observed concentration of drug. A PK substudy was conducted in at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. For each participant, PK samples were taken at only one of the three possible visits: Weeks 16, 22, or 28. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
| ng/mL | Group 3: Oral LEN + F/TAF |
|---|---|
| TAF | 308.7 ± 74.7 |
| TFV | 31.2 ± 51.7 |
Tmax is defined as the time (observed time point) of Cmax. A PK substudy was conducted in at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. For each participant, PK samples were taken at only one of the three possible visits: Weeks 16, 22, or 28. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
| hours | Group 3: Oral LEN + F/TAF |
|---|---|
| TAF | 0.53 (0.50 to 1.04) |
| TFV | 1.00 (1.00 to 2.00) |
Clast is defined as the last observable concentration of drug. A PK substudy was conducted in at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TFV was summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. For each participant, PK samples were taken at only one of the three possible visits: Weeks 16, 22, or 28. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
| ng/mL | Group 3: Oral LEN + F/TAF |
|---|---|
| PK of TFV: Clast at Weeks 16, 22, or 28 | 22.2 ± 62.6 |
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF was summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 at Week 38.
| h*ng/mL | Group 1: SC LEN+(F/TAF→ TAF) |
|---|---|
| PK of TAF: AUClast at Week 38 | 211.5 ± 74.1 |
Cmax is defined as the maximum observed concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF was summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 at Week 38.
| ng/mL | Group 1: SC LEN+(F/TAF→ TAF) |
|---|---|
| PK of TAF: Cmax at Week 38 | 279.0 ± 67.8 |
Tmax is defined as the time (observed time point) of Cmax. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF was summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 at Week 38.
| hours | Group 1: SC LEN+(F/TAF→ TAF) |
|---|---|
| PK of TAF: Tmax at Week 38 | 0.50 (0.50 to 0.50) |
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A peripheral blood mononuclear cell (PBMC) substudy was conducted in a total of approximately 15 participants in Treatment Groups 1 and 2. For each participant, PK samples were taken at only one of the four possible visits: Weeks 4, 10, 16, or 22. A 12-hour postdose sample was collected, if possible. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
| h*μM | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) |
|---|---|---|
| PK of Tenofovir Diphosphate (TFV-DP): AUClast at Weeks 4, 10, 16, or 22 | 16.2 ± 68.3 | 21.6 ± 71.9 |
Cmax is defined as the maximum observed concentration of drug. A PBMC substudy was conducted in a total of approximately 15 participants in Treatment Groups 1 and 2. For each participant, PK samples were taken at only one of the four possible visits: Weeks 4, 10, 16, or 22. A 12-hour postdose sample was collected, if possible. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
| micrometer (μM) | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) |
|---|---|---|
| PK of TFV-DP: Cmax at Weeks 4, 10, 16, or 22 | 3.3 ± 37.5 | 4.3 ± 71.8 |
Tmax is defined as the time (observed time point) of Cmax. A PBMC substudy was conducted in a total of approximately 15 participants in Treatment Groups 1 and 2. For each participant, PK samples were taken at only one of the four possible visits: Weeks 4, 10, 16, or 22. A 12-hour postdose sample was collected, if possible. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
| hours | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) |
|---|---|---|
| PK of TFV-DP: Tmax at Weeks 4, 10, 16, or 22 | 2.00 (1.00 to 6.00) | 6.00 (1.00 to 6.00) |
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). At Week 38, samples were analyzed for BIC only in Treatment Group 2.
| h*ng/mL | Group 2: SC LEN + (F/TAF → BIC) |
|---|---|
| PK of Bictegravir (BIC): AUClast at Week 38 | 72865.9 ± 31.0 |
Cmax is defined as the maximum observed concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). At Week 38, samples were analyzed for BIC only in Treatment Group 2.
| ng/mL | Group 2: SC LEN + (F/TAF → BIC) |
|---|---|
| PK of BIC: Cmax at Week 38 | 10180.0 ± 42.8 |
Tmax is defined as the time (observed time point) of Cmax. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). At Week 38, samples were analyzed for BIC only in Treatment Group 2.
| hours | Group 2: SC LEN + (F/TAF → BIC) |
|---|---|
| PK of BIC: Tmax at Week 38 | 2.00 (1.00 to 3.00) |
Clast is defined as the last observable concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). At Week 38, samples were analyzed for BIC only in Treatment Group 2.
| ng/mL | Group 2: SC LEN + (F/TAF → BIC) |
|---|---|
| PK of BIC: Clast at Week 38 | 8474.5 ± 33.3 |
Collected over Adverse Events: Up to 174.9 weeks ; All-Cause Mortality: Up to 189 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: SC LEN+(F/TAF→ TAF) | 1/52 (1.9%) | 4/52 (7.7%) | 47/52 (90.4%) |
| Group 2: SC LEN + (F/TAF → BIC) | 0/53 (0%) | 4/53 (7.5%) | 46/53 (86.8%) |
| Group 3: Oral LEN + F/TAF | 1/52 (1.9%) | 7/52 (13.5%) | 42/52 (80.8%) |
| Group 4: B/F/TAF | 0/26 (0%) | 0/25 (0%) | 19/25 (76%) |
| Event | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF |
|---|---|---|---|---|
| Lymphadenopathy mediastinalBlood and lymphatic system disorders | 1/52 | 0/53 | 0/52 | 0/25 |
| VomitingGastrointestinal disorders | 1/52 | 0/53 | 0/52 | 0/25 |
| DeathGeneral disorders | 0/52 | 0/53 | 1/52 | 0/25 |
| CholecystitisHepatobiliary disorders | 1/52 | 0/53 | 0/52 | 0/25 |
| AppendicitisInfections and infestations | 0/52 | 0/53 | 1/52 | 0/25 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 0/52 | 0/53 | 1/52 | 0/25 |
| PneumoniaInfections and infestations | 1/52 | 0/53 | 0/52 | 0/25 |
| Staphylococcal infectionInfections and infestations | 1/52 | 0/53 | 0/52 | 0/25 |
| PoisoningInjury, poisoning and procedural complications | 0/52 | 0/53 | 1/52 | 0/25 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 1/52 | 0/53 | 0/52 | 0/25 |
| Event | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF |
|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 25/52 | 18/53 | 0/52 | 0/25 |
| Injection site swellingGeneral disorders | 17/52 | 18/53 | 0/52 | 0/25 |
| Injection site painGeneral disorders | 15/52 | 14/53 | 0/52 | 0/25 |
| InfluenzaInfections and infestations | 13/52 | 5/53 | 11/52 | 0/25 |
| Injection site noduleGeneral disorders | 11/52 | 13/53 | 0/52 | 0/25 |
| Injection site inflammationGeneral disorders | 12/52 | 4/53 | 0/52 | 0/25 |
| Injection site indurationGeneral disorders | 11/52 | 11/53 | 0/52 | 0/25 |
| Covid-19Infections and infestations | 10/52 | 9/53 | 11/52 | 4/25 |
| NauseaGastrointestinal disorders | 10/52 | 5/53 | 7/52 | 1/25 |
| HeadacheNervous system disorders | 10/52 | 8/53 | 9/52 | 3/25 |
Safety Analysis Set included all participants who were randomized and received at least 1 dose of study drug.
| Age, Categorical(Participants) | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 52 | 53 | 51 | 25 | 181 |
| >=65 years | 0 | 0 | 1 | 0 | 1 |
| Age, Continuous(years) | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF | Total |
|---|---|---|---|---|---|
| Mean | 33 ± 9.5 | 30 ± 8.8 | 32 ± 12.3 | 33 ± 11.1 | 32 ± 10.4 |
| Sex: Female, Male(Participants) | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF | Total |
|---|---|---|---|---|---|
| Female | 5 | 1 | 6 | 0 | 12 |
| Male | 47 | 52 | 46 | 25 | 170 |
| Race/Ethnicity, Customized(Participants) | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF | Total |
|---|---|---|---|---|---|
| Race — American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Race — Asian | 1 | 0 | 1 | 0 | 2 |
| Race — Black | 24 | 24 | 31 | 16 | 95 |
| Race — Native Hawaiian or Pacific Islander | 1 | 1 | 0 | 0 | 2 |
| Race — White | 23 | 28 | 19 | 8 | 78 |
| Race — Other | 2 | 0 | 1 | 1 | 4 |
| Race/Ethnicity, Customized(Participants) | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF | Total |
|---|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 25 | 21 | 24 | 12 | 82 |
| Ethnicity — Not Hispanic or Latino | 27 | 32 | 28 | 13 | 100 |
| Region of Enrollment(Participants) | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF | Total |
|---|---|---|---|---|---|
| Puerto Rico | 1 | 1 | 5 | 1 | 8 |
| United States | 37 | 42 | 37 | 21 | 137 |
| Dominican Republic | 14 | 10 | 10 | 3 | 37 |
| Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA)(log10 copies/mL) | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF | Total |
|---|---|---|---|---|---|
| Mean | 4.18 ± 0.672 | 4.35 ± 0.670 | 4.33 ± 0.722 | 4.35 ± 0.780 | 4.30 ± 0.700 |
| HIV-1 RNA Categories(Participants) | Group 1: SC LEN+(F/TAF→ TAF) | Group 2: SC LEN + (F/TAF → BIC) | Group 3: Oral LEN + F/TAF | Group 4: B/F/TAF | Total |
|---|---|---|---|---|---|
| <= 100,000 copies/mL | 47 | 44 | 43 | 21 | 155 |
| > 100,000 copies/mL | 5 | 9 | 9 | 4 | 27 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gileadclinicaltrials.com
Ran from Nov 2019 to primary completion in Oct 2021, 22 months.
Results were first posted in Dec 2022, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lenacapavir · Bictegravir · Emtricitabine · Tenofovir alafenamide